Erythromycin Therapy for Group A Streptococcal Pharyngitis: Results of a Comparative Study of the Estolate and Ethylsuccinate Formulations

C. M. Ginsburg, G. H. McCracken, S. D. Crow, B. R. Dildy, G. Morchower, J. B. Steinberg, K. Lancaster

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

One hundred two children with group A streptococcal pharyngitis were treated on a randomized basis with either 15 mg/kg of erythromycin estolate or 25 mg/kg of erythromycin ethylsuccinate given twice daily for ten days. Twelve patients, including 11 erythromycin ethylsuccinate—treated patients and one erythromycin estolate—treated patient, were dropped from the study at the request of their parents because of abdominal cramping and/or nausea and vomiting that occurred 15 to 45 minutes after ingestion of drug. Eighteen other patients had similar gastrointestinal tract symptoms that resolved or abated. Excluding patients with reinfections with new streptococcal serotypes and those with resistant strains, the bacteriologic failure rates were 4.3% and 17.5%, and the total failure rates were 6.4% and 35.3% with erythromycin estolate therapy and with erythromycin ethylsuccinate therapy, respectively. The high rate of GI tract intolerance associated with the erythromycin ethylsuccinate appears to be dose related.

Original languageEnglish (US)
Pages (from-to)536-539
Number of pages4
JournalAmerican Journal of Diseases of Children
Volume138
Issue number6
DOIs
StatePublished - Jun 1984

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Erythromycin Therapy for Group A Streptococcal Pharyngitis: Results of a Comparative Study of the Estolate and Ethylsuccinate Formulations'. Together they form a unique fingerprint.

  • Cite this